• 1
    APASL Hepatitis C Working Party. APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J. Gastroenterol. Hepatol. 2007; 22: 61533.
  • 2
    Farrell GC, Liaw YF, McCaughan GW. JGH and Asia–Pacific consensus on prevention and management of gastrointestinal and liver diseases. J. Gastroenterol. Hepatol. 2000; 15: 81518.
  • 3
    Core Working Party for Asia–Pacific Consensus on Hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia–Pacific region. J. Gastroenterol. Hepatol. 2000; 15: 82541.
  • 4
    National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002–June 10–12, 2002. Hepatology 2002; 36 (Suppl. 1): S320. Available from URL:
  • 5
    Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). Consensus conference. Treatment of hepatitis C. Gastroenterol. Clin. Biol. 2002; 26: B30320 (in French). Available from URL: (in English).
  • 6
    Orlent H, Vrolijk JM, Veldt BJ, Schalm SW. Hepatitis C 2002 guidelines: summary and annotations. Scand. J. Gastroenterol. Suppl. 2003; 239: 10510.
  • 7
    Coverdale SA, Khan MH, Byth K et al. Effects of interferon treatment response on liver complications of chronic hepatitis C. 9-year follow-up study. Am. J. Gastroenterol. 2004; 99: 63644.
    Direct Link:
  • 8
    Imazeki F, Yokosuka O, Fukai K et al. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. 2005; 25: 7728.
  • 9
    Farrell GC. Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: flaws in the cure, or clues to the flaw? J. Gastroenterol. Hepatol. 1999; 14: 8337.
  • 10
    Tokita H, Fukui H, Tanaka A et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J. Gastroenterol. Hepatol. 2005; 20: 7528.
  • 11
    Mizokami M, Tanaka Y, Miyakawa Y. Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds. Intervirology 2006; 49: 2836.
  • 12
    Tsai MC, Kee KM, Chen YD et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J. Gastroenterol. Hepatol. 2007; 22: 928.
  • 13
    Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J. Clin. Virol. 2003; 26: 17184.
  • 14
    Garten RJ, Zhang J, Lai S, Liu W, Chen J, Yu XF. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin. Infect. Dis. 2005; 41 (Suppl. 1): S1824.
  • 15
    Qian HZ, Vermund SH, Kaslow RA et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS 2006; 20: 142935.
  • 16
    Li C, Fu Y, Lu L et al. Complete genomic sequences for hepatitis C virus subtypes 6e and 6g isolated from Chinese patients with injection drug use and HIV-1 co-infection. J. Med. Virol. 2006; 78: 10619.
  • 17
    Satoh Y, Hino K, Kato T et al. Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan. J. Gastroenterol. Hepatol. 2004; 19: 130511.
  • 18
    Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am. J. Public Health 2005; 95: 17379.
  • 19
    Arora S, O'Brien C, Zeuzem S et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J. Gastroenterol. Hepatol. 2006; 21: 40612.
  • 20
    Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 34655.
  • 21
    Poustchi H, Negro F, Hui J, Kench J, George JS. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J. Gastroenterol. Hepatol. 2006; 21 (Suppl. 6): A444.
  • 22
    Knott A, Dieperink E, Willenbring ML et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am. J. Gastroenterol. 2006; 101: 225462.
    Direct Link:
  • 23
    Hallinen R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J. Gastroenterol. Hepatol. 2005; 20: 10826.
  • 24
    Kumar D, Wallington-Beddoe C, Farrell GC et al. Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting Med. J. Aust. 2003; 178: 26771.
  • 25
    Ishikawa T, Fukushima Y, Shiobara Y et al. Outbreak of hepatitis C virus infection in an outpatient clinic. J. Gastroenterol. Hepatol. 2005; 20: 108793.
  • 26
    Kokoglu OF, Ucmak H, Hosoglu S et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2006; 21: 57580.
  • 27
    Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertially acquired and post-transfusion hepatitis C infection in children. J. Gastroenterol. Hepatol. 2004; 19: 137562.
  • 28
    Hung CH, Lee CM, Lu SN et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J. Gastroenterol. Hepatol. 2005; 20: 72732.
  • 29
    Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J. Hepatol. 2006; 44 (Suppl.): S1329.
  • 30
    Boseley S. Scientists on a mission to bring cheap drugs to the world's poorest countries. Guardian Weekly 2 January 2007. Available from URL:,1981356,00.html
  • 31
    Farrell GC. Expanding horizons for the Journal: the role of the Journal of Gastroenterology and Hepatology Foundation. J. Gastroenterol. Hepatol. 2003; 18:2356.